alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Third District Court of Appeal

State of Florida

Opinion filed July 20, 2022.

Not final until disposition of timely filed motion for rehearing.

________________

No. 3D22-0406

Lower Tribunal No. F98-42611

________________

Billy Lamont Culpepper,

Appellant,

vs.

The State of Florida,

Appellee.

An Appeal under Florida Rule of Appellate Procedure 9.141(b)(2) from 

the Circuit Court for Miami-Dade County, Carmen Cabarga, Judge.

Billy Lamont Culpepper, in proper person.

Ashley Moody, Attorney General, and Michael W. Mervine, Chief 

Assistant Attorney General, for appellee.

Before LINDSEY, HENDON, and LOBREE, JJ. 

PER CURIAM.

Affirmed.
| Home  |  Publications  |  Topic index  |  Surveys  |  Databases  |  Search |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Keep Current!  Subscribe to NSF's Custom News Service |
|-------------------------------------------------------|
 

# Federal Research and Development Funding by Budget Function

-   Archived Publications     - President's FY 2001 Budget Asks for an Increase in R&D Funding *(NSF 00-324)* 
  - Federal Research and Development Funding by Budget Function: Fiscal Years 1999-2001 *(NSF 01-316)* 
  - Federal Research and Development Funding         by Budget Function: Fiscal Years 1999-2001 *[Early Release Tables]* 
  - President's FY 2000 Budget Includes Reduced R&D Request; Nondefense R&D Funding Catches Up to Defense R&D *(NSF 99-353)* 
  - Federal Research and Development Funding by Budget Function: Fiscal Years 1998-2000 *(NSF 00-303)* 
  - Federal Research and Development Funding by Budget Function:  Fiscal Years 1998-2000 *[Early Release Tables]*
  - President's FY 1999 Budget Keeps R&D         Spending at Last Year's Level When Adjusted for Inflation *(NSF 98-329)* 
  - Federal Research and Development Funding         by Budget Function: Fiscal Years 1997-99 *(NSF 99-315)* 
  - President's FY 1998 Budget Asks for         Slightly Lower Inflation-Adjusted R&D Spending *(NSF 97-320)*
  - Federal Research and Development Funding         by Budget Function: Fiscal Years 1996-98 *(NSF 98-301)*
  - President's Budget Includes Small Increase         for R&D in FY 1997 *(NSF 96-323)* 
  - Statistical Tables on Federal Research         and Development (R&D) Funding by Budget Function: Fiscal Years 1995-97         *[Early Release Tables]* 
  - Federal Research and Development Funding         by Budget Function: 1994-1996, *(NSF 95-342)* 
  - Federal Research and Development Funding         by Budget Function: 1993-1995, *(NSF 94-319)* 

 Return to the Federal Research and Development Funding by Budget Function series page.

Contact SRS
§ 111.460 What requirements apply to holding in-process material? ( a ) You must identify and hold in-process material under conditions that protect against mixup, contamination, and deterioration.
( b ) You must hold in-process material under appropriate conditions of temperature, humidity, and light.
#### § 5800.765 May I ask the suspending official to reconsider a decision to suspend me?

Yes. Within 30 days of receiving a final notice of suspension, you may make a written request for the suspending official to reconsider your suspension.
H. Res. 778

In the House of Representatives, U.S., 

April 26, 2006.

Resolved, That the following named Member be, and is 

hereby, elected to the following standing committee of the 

House of Representatives: 

COMMITTEE ON STANDARDS OF OFFICIAL CONDUCT: 

Mr. Berman (to rank immediately ahead of Mrs. Jones of 

Ohio).

Attest: 

Clerk.
Editorial Note on Part 14
Editorial Note: Nomenclature changes to part 14 appear at 88 FR 45065, July 14, 2023.

§ 14.160 Establishment of standing technical advisory committees for human prescription drugs. The standing technical advisory committees for human prescription drugs are established to advise the Commissioner: ( a ) Generally on the safety and effectiveness, including the labeling and advertising, and regulatory control of the human prescription drugs falling within the pharmacologic class covered by the advisory committee and on the scientific standards appropriate for a determination of safety and effectiveness in that class of drugs.
( b ) Specifically on any particular matter involving a human prescription drug pending before FDA, including whether the available information is adequate to support a determination that— ( 1 ) A particular IND study may properly be conducted;
( 2 ) A particular drug meets the statutory standard for proof of safety and effectiveness necessary for approval or continued approval for marketing; or
( 3 ) A particular drug is properly classified as a new drug, an old drug, or a banned drug.
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 9 Engrossed in House (EH)]

                 In the House of Representatives, U.S.,

                                                       January 4, 2005.
    Resolved, That at 10:30 a.m. on Thursday, January 20, 2005, the House shall 
proceed to the West Front of the Capitol for the purpose of attending the 
inaugural ceremonies of the President and Vice President of the United States; 
and that upon the conclusion of the ceremonies the House stands adjourned until 
2 p.m. on Tuesday, January 25, 2005, pursuant to such concurrent resolution of 
adjournment as may so permit.
            Attest:

                                                                          Clerk.
```
Ex-10.11



 







EXHIBIT 10.11




AMENDMENT NO. 1

TO

REYNOLDS AMERICAN INC.

ANNUAL INCENTIVE AWARD PLAN

(Amended and Restated as of January 1, 2006)




     1. The first sentence of Section 9(e) of the Plan is deleted in its entirety and the
following language is inserted in place thereof:




	 	 	 	“If the number of shares of Common Stock is increased or decreased as a result of any stock
dividend, subdivision or reclassification of shares, the number of shares of Common Stock to
which each Participant’s Common Stock credit account is equivalent shall be increased in
proportion to the increase or decrease in the number of outstanding shares of Common Stock
and the Closing Price on which payments hereunder is based will be proportionately decreased
or increased.”





     2. All references to the Plan shall be deemed to refer to the Plan as amended by this
Amendment No. 1.



     3. Except as specifically amended hereby, the original provisions of the Plan shall remain
in full force and effect.



     4. This Amendment No. 1 shall be effective as of July 18, 2006.



	 	 	 	 	 
	 

	 	REYNOLDS AMERICAN INC.
	 
	 	 	 	 
	 

	 	By:
	 	/s/ McDara P. Folan, III
	 

	 	 	 	 
	 

	 	 	 	Name: McDara P. Folan, III

Title:   Senior Vice President, Deputy General Counsel and

            Secretary
Bending Under Pressure

Be an engineer and devise ways to

make joints in some long, inflated

balloons.

Materials:

2 long balloons

3 thick rubber bands

Procedure:

1. Inflate one balloon fully 

and tie it.

2. Inflate the second balloon.

While it is inflating,

slide the rubber bands 

over the balloon so that 

the balloon looks like 

sausage links. Doubling 

the rubber bands at each 

“link” will yield the best 

results.

3. Compare the “bendability”

of the two balloons. Can 

you find other ways to 

make the inflated balloons 

more bendable?

Where would engineers place joints

to help astronauts work in space?

Suited for Spacewalking

http://www.spaceflight.nasa.gov

A spacesuit must have the proper

pressure for astronaut survival.

However, in an inflated spacesuit,

it can be difficult to bend and move

arms, legs, and fingers. The spacesuit is like an inflated balloon with 

an astronaut inside. The more 

pressure in the balloon, the more 

difficult the balloon is to bend.

NASA engineers had to overcome 

the problem of a stiff, unbendable

spacesuit so astronauts could 

work in space. Engineers built in

joints, like ribs on vacuum cleaner

hoses, to make suits more flexible.

Access the Suited for Spacewalking

Educator Guide via the Internet at

http://spacelink.nasa.gov/products.

Additional information can be found at

http://spaceflight.nasa.gov

ET-2001-09-010-HQ

National Aeronautics and 

Space Administration

Cut along the brown area, fold along black line >

< Cut along the brown area, fold along black line 

✁

✁
1

Filed 5/3/23 P. v. Cage CA3

NOT TO BE PUBLISHED

California Rules of Court, rule 8.1115(a), prohibits courts and parties from citing or relying on opinions not certified for 

publication or ordered published, except as specified by rule 8.1115(b). This opinion has not been certified for publication 

or ordered published for purposes of rule 8.1115.

IN THE COURT OF APPEAL OF THE STATE OF CALIFORNIA

THIRD APPELLATE DISTRICT

(Sacramento)

----

THE PEOPLE,

Plaintiff and Respondent,

v.

JIM CAGE,

Defendant and Appellant.

C097197

(Super. Ct. No. 07F02966)

Defendant Jim Cage appeals the trial court’s denial of his petition for resentencing 

under Penal Code section 1172.6.

1

 Appellate counsel filed a brief raising no arguable 

issues under People v. Delgadillo (2022) 14 Cal.5th 216, and requesting we exercise our 

discretion to review the entire record for arguable issues on appeal.

1

 Defendant petitioned for resentencing under former section 1170.95. Effective 

June 30, 2022, the Legislature renumbered former section 1170.95 as section 1172.6 

without substantive changes. (Stats. 2022, ch. 58, § 10.)
2

On December 31, 2022, appellate counsel wrote defendant explaining she would 

be filing a Delgadillo brief, and if defendant failed to file a propria persona supplemental 

brief, his appeal would likely be dismissed as abandoned. On February 3, 2023, this 

court sent a letter notifying defendant: (1) his counsel filed an appellate brief stating her 

review of the record did not identify any arguable issues; (2) as a case arising from an 

order denying postconviction relief, defendant was not constitutionally entitled to counsel 

or to an independent review of the record; and (3) in accordance with the procedures set 

forth in Delgadillo, defendant had 30 days to file a supplemental brief or letter raising 

any argument he wanted this court to consider. In addition, we notified defendant if this 

court did not receive a letter or brief within that 30-day period, the court may dismiss his 

appeal as abandoned. More than 30 days have elapsed and we have received no 

communication from defendant.

We consider defendant’s appeal abandoned and order the appeal dismissed. 

(People v. Delgadillo, supra, 14 Cal.5th at p. 232.)
3

DISPOSITION

The appeal is dismissed.

 /s/

HORST, J.

We concur:

 /s/

RENNER, Acting P.J.

 /s/

BOULWARE EURIE, J.



 Judge of the Placer County Superior Court, assigned by the Chief Justice pursuant to 

article VI, section 6 of the California Constitution.
Table of Contents

Exhibit32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION1350, AS ADOPTED PURSUANT TO SECTION 906 OF THESARBANES-OXLEY ACT OF 2002

In connection with the QuarterlyReport of Hutton Investors Futures Fund L.P. II (the‘‘Partnership’’) on Form 10-Q for the periodending June 30, 2006 as filed with the Securities and ExchangeCommission on the date hereof (the ‘‘Report’’),I, Daniel R. McAuliffe, Jr., Chief Financial Officer and Director ofCitigroup Managed Futures LLC, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of2002, that:

(1) The Report fully complies with therequirements of section 13(a) or 15(d) of the Securities Exchange Actof 1934; and

(2) The information contained in the Reportfairly presents, in all material respects, the financial condition andresults of operations of the Partnership.

/s/Daniel R. McAuliffe,Jr.

|  |
|--|
|  |  |
|  |

Daniel R. McAuliffe,Jr.Citigroup Managed Futures LLC Chief Financial Officer andDirector

Date: August 14,2006

----
| (logo) WELLS

           FARGO

  | Commercial Mortgage Servicing

D1086-120, 12th Floor

550 South Tryon Street

Charlotte, NC 28202

1-800-326-1334

  |
|------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|

 

 

ANNUAL STATEMENT OF COMPLIANCE

 

Reference is hereby made to that certain Pooling and Servicing Agreement dated as of March 1, 2013, by and among DEUTSCHE MORTGAGE & ASSET RECEIVING CORPORATION, as Depositor, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Master Servicer, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Special Servicer, U.S. BANK NATIONAL ASSOCIATION, as Trustee, and DEUTSCHE BANK AND TRUST COMPANY AMERICAS, as Certificate Administrator, Paying Agent and Custodian with respect to Commercial Mortgage Pass-Through Certificates, Series COMM 2013-CCRE6 (the "Agreement"). Capitalized terms used herein not otherwise defined shall have the meanings assigned in the Agreement.

 

Pursuant to Section 10.11 of this Agreement, I, Lea Land, Director of Commercial Mortgage Services do hereby certify that:

 

1.        A review of the activities of the Special Servicer during the period from January 1, 2014 through December 31, 2014 (the “Reporting Period”),  and of its performance per the Agreement during such period has been made under my supervision, and

 

2.        To the best of my knowledge, based on such review, the Special Servicer has fulfilled all of its obligations under this Agreement in all material respects throughout the Reporting Period.

 

 

 

IN WITNESS WHEREOF, the undersigned has executed this Certificate as of the 6th day of March 2015.

 

 

 

/s/ Lea Land 

Lea Land, Director

Wells Fargo Bank

 

 
| Wells Fargo Bank, N.A. | (logo) Together we’ll go far |
|------------------------|------------------------------------|
# L_2019227DE.01002601.xml

| 3.9.2019 | DE | Amtsblatt der Europäischen Union | L 227/26 |
| --- | --- | --- | --- |

3.9.2019

DE

Amtsblatt der Europäischen Union

L 227/26

---

Berichtigung der Leitlinie (EU) 2018/876 der Europäischen Zentralbank vom 1. Juni 2018 zum Datenregister über Institute und verbundene Unternehmen (EZB/2018/16)

(
  Amtsblatt der Europäischen Union L 154 vom 18. Juni 2018
  )

Seite 11, Artikel 15 Absatz 2:

Anstatt:

„(2)   Beziehungen zwischen IFs und Managementgesellschaften und zwischen Teil- und Dachfonds sind, soweit einschlägig, in RIAD zu erfassen.“

muss es heißen:

„(2)   Beziehungen zwischen IFs und Verwaltungsgesellschaften und zwischen Teil- und Dachfonds sind, soweit einschlägig, in RIAD zu erfassen.“

Seite 11, Artikel 16 Absatz 2:

Anstatt:

„(2)   Beziehungen zwischen FMKGs und Managementgesellschaften sowie zwischen FMKGs und Originatoren sind gegebenenfalls in RIAD zu erfassen.“

muss es heißen:

„(2)   Beziehungen zwischen FMKGs und Verwaltungsgesellschaften sowie zwischen FMKGs und Originatoren sind gegebenenfalls in RIAD zu erfassen.“

---
§ 111.23 Under this subpart C, what records must you make and keep? ( a ) You must make and keep records required under this subpart C in accordance with subpart P of this part.
( b ) You must make and keep records of the written procedures for cleaning the physical plant and for pest control.
( c ) You must make and keep records that show that water, when used in a manner such that the water may become a component of the dietary supplement, meets the requirements of § 111.15(e)(2).
#### § 2424.1165 How is a limited denial of participation reported?

When a limited denial of participation has been made final, or the period for requesting a conference pursuant to § 2424.1130 has expired without receipt of such a request, the official imposing the limited denial of participation shall notify the Director of the Compliance Division in the Departmental Enforcement Center of the scope of the limited denial of participation.
[Federal Register Volume 76, Number 3 (Wednesday, January 5, 2011)]
[Notices]
[Page 576]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-33291]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of a meeting of the 
President's Cancer Panel.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: President's Cancer Panel.
    Date: February 1, 2011.
    Time: 8 a.m. to 4 p.m.
    Agenda: The Future of Cancer Research: Accelerating Scientific 
Innovation.
    Place: Grand Hyatt Atlanta, 3300 Peachtree Road, NE., Atlanta, 
GA 30305.
    Contact Person: Abby B. Sandler, PhD, Executive Secretary, 
Chief, Institute Review Office, Office of the Director, 6116 
Executive Blvd., Suite 220, MSC 8349, National Cancer Institute, 
NIH, Bethesda, MD 20892-8349, (301) 451-9399, <a href="/cdn-cgi/l/email-protection#0477656a60686176654469656d682a6a6d6c2a636b72"><span class="__cf_email__" data-cfemail="8cffede2e8e0e9feedcce1ede5e0a2e2e5e4a2ebe3fa">[email protected]</span></a>.
    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    Information is also available on the Institute's/Center's home 
page: deainfo.nci.nih.gov/advisory/pcp/pcp.htm, where an agenda and 
any additional information for the meeting will be posted when 
available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: December 28, 2010.
Anna P. Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-33291 Filed 1-4-11; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
H. Res. 240 

In the House of Representatives, U. S., 

April 4, 2017. 

Resolved, That upon adoption of this resolution it shall 

be in order to consider in the House the bill (H.R. 1343) to 

direct the Securities and Exchange Commission to revise its 

rules so as to increase the threshold amount for requiring 

issuers to provide certain disclosures relating to compensatory 

benefit plans. All points of order against consideration of the 

bill are waived. An amendment in the nature of a substitute 

consisting of the text of Rules Committee Print 115–11 shall 

be considered as adopted. The bill, as amended, shall be considered as read. All points of order against provisions in the 

bill, as amended, are waived. The previous question shall be 

considered as ordered on the bill, as amended, and on any 

further amendment thereto, to final passage without intervening motion except: (1) one hour of debate equally divided 

and controlled by the chair and ranking minority member of 

the Committee on Financial Services; (2) the further amendment printed in the report of the Committee on Rules accompanying this resolution, if offered by the Member designated 
2 

•HRES 240 EH 

in the report, which shall be in order without intervention of 

any point of order, shall be considered as read, shall be separately debatable for the time specified in the report equally 

divided and controlled by the proponent and an opponent, 

and shall not be subject to a demand for a division of the 

question; and (3) one motion to recommit with or without instructions. 

Attest: 

Clerk.
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 465 Introduced in House (IH)]

<DOC>

115th CONGRESS
  1st Session
H. RES. 465

Expressing the sense of the House of Representatives that regular order 
              should be restored in the House and Senate.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             July 20, 2017

Mr. Nolan submitted the following resolution; which was referred to the 
                           Committee on Rules

_______________________________________________________________________

                               RESOLUTION

 
Expressing the sense of the House of Representatives that regular order 
              should be restored in the House and Senate.

    Resolved,

SECTION 1. REQUIRING REGULAR ORDER IN THE HOUSE AND SENATE.

    It is the sense of the House of Representatives that--
            (1) it should not be in order to consider a bill or 
        resolution in the House unless each committee to which the bill 
        or resolution is referred--
                    (A) had a hearing on the bill or resolution at 
                which amendments were permitted to be offered and 
                debated and a vote was taken on each amendment offered 
                and on final passage; and
                    (B) filed a report with respect to the bill or 
                resolution;
            (2) a conference report should not be filed in the House 
        unless--
                    (A) the conference committee held at least 3 
                meetings in which all members of the conference 
                committee were allowed to be present;
                    (B) all items of difference between the House and 
                Senate were addressed, voted on, and resolved by the 
                full conference committee membership; and
                    (C) printed or electronic copies of the conference 
                report and the accompanying joint explanatory statement 
                were available to Members and Delegates for at least 48 
                hours prior to filing;
            (3) the House and Senate should schedule simultaneous 5-day 
        work weeks in Washington and district work periods; and
            (4) every bill brought to committee should be open to 
        amendment and every bill brought to the floor of the House for 
        a vote should be considered under an open rule.
                                 <all>
```